Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
15.62
-0.30 (-1.88%)
At close: Apr 28, 2026, 4:00 PM EDT
15.63
+0.01 (0.06%)
After-hours: Apr 28, 2026, 5:53 PM EDT
Corvus Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 9.25 | 8.16 | 6.8 | 7.51 | 9.28 | |
| Research & Development | 33.72 | 19.39 | 16.53 | 24.47 | 29.12 | |
| Operating Expenses | 42.97 | 27.55 | 23.33 | 31.98 | 38.4 | |
| Operating Income | -42.97 | -27.55 | -23.33 | -31.98 | -38.4 | |
| Interest & Investment Income | 2.51 | 1.82 | 1.58 | 0.65 | - | |
| Earnings From Equity Investments | -1.96 | -3.2 | -5.28 | -10.01 | -4.83 | |
| Other Non Operating Income (Expenses) | 27.14 | -33.38 | - | - | -0.02 | |
| EBT Excluding Unusual Items | -15.28 | -62.3 | -27.03 | -41.33 | -43.24 | |
| Gain (Loss) on Sale of Assets | - | 0.01 | - | 0.02 | - | |
| Pretax Income | -15.28 | -62.29 | -27.03 | -41.31 | -43.24 | |
| Net Income | -15.28 | -62.29 | -27.03 | -41.31 | -43.24 | |
| Net Income to Common | -15.28 | -62.29 | -27.03 | -41.31 | -43.24 | |
| Shares Outstanding (Basic) | 79 | 61 | 48 | 47 | 42 | |
| Shares Outstanding (Diluted) | 80 | 61 | 48 | 47 | 42 | |
| Shares Change (YoY) | 30.76% | 26.99% | 3.16% | 11.23% | 41.98% | |
| EPS (Basic) | -0.19 | -1.02 | -0.56 | -0.89 | -1.03 | |
| EPS (Diluted) | -0.53 | -1.02 | -0.56 | -0.89 | -1.03 | |
| Free Cash Flow | -32.97 | -25.42 | -23.97 | -27.29 | -36.72 | |
| Free Cash Flow Per Share | -0.41 | -0.42 | -0.50 | -0.59 | -0.88 | |
| EBITDA | -42.87 | -27.46 | -23.18 | -31.61 | -37.94 | |
| D&A For EBITDA | 0.11 | 0.09 | 0.15 | 0.37 | 0.46 | |
| EBIT | -42.97 | -27.55 | -23.33 | -31.98 | -38.4 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.